Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 11Phase 1/2 6Phase NA 2Phase 2/3 2Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Breast 3Other hematologic neoplasm 2Myeloid 2Thoracic 1Other solid neoplasm 1NET 1Gynecologic 1Genitourinary 1Endocrine 1

Conditions

Myelodysplastic Syndromes 1Mastocytosis 1Leukemia, Myeloid, Acute 1GATA2 Deficiency 1

Interventions

fludarabine phosphate 5Cyclophosphamide 5Azacitidine 4Thiotepa 3Stem Cell Transplantation 3Melphalan 3Gemtuzumab 3Decitabine 3Cytarabine 3Busulfan 3venetoclax 2Radiotherapy 2Methylprednisolone 2Interferon alpha-2 2Injections 2Filgrastim 2Etoposide 2Emapalumab 2Cyclosporine 2Cladribine 2Antilymphocyte Serum 2vosaroxin 1vedolizumab 1trametinib 1tipifarnib 1thymoglobulin 1peginterferon alfa-2b 1peginterferon alfa-2a 1nilotinib 1midostaurin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Injections × Myeloid × Clear all
NCT03092674 2025-01-16

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2/3 Completed
76 enrolled 16 charts
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01333293 2016-01-18

XOLMA

University of Zurich

Phase 2/3 Completed
17 enrolled
Myeloid

Mastocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡